KalVista Pharmaceuticals Announces Proposed $110 Million Convertible Senior Notes Offering, With Option for Additional $15 Million
Reuters
Sep 25
KalVista Pharmaceuticals Announces Proposed $110 Million Convertible Senior Notes Offering, With Option for Additional $15 Million
KalVista Pharmaceuticals Inc. (NASDAQ: KALV) has announced a proposed private offering of $110 million aggregate principal amount of Convertible Senior Notes due 2031. The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. KalVista has also granted initial purchasers an option to purchase up to an additional $15 million aggregate principal amount of notes within 13 days of the initial issuance. The interest rate, initial conversion rate, offering price, and other terms will be determined upon pricing of the notes. The proceeds are intended for working capital, general corporate purposes, and potential future investments or acquisitions. Holders will have repurchase rights upon a fundamental change, and the conversion rate may increase in certain circumstances. The full prospectus URL is not included in the document.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250924848884) on September 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.